Detail akcie Vigil Neuro Rg online

Business Summary: Vigil Neuroscience, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based therapies to improve the lives of patients and their families. Its lead clinical candidate, VGL101 (iluzanebart), is a fully human monoclonal antibody TREM2 agonist that is being studied in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. The Company is also developing VG-3927, its orally available small molecule TREM2 agonist program to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease in genetically defined subpopulations.
Financial Summary: BRIEF: For the three months ended 31 March 2024, Vigil Neuroscience Inc revenues was not reported. Net loss increased 1% to $19.9M. Higher net loss reflects Stock-based Compensation in SGA increase of 46% to $1.5M (expense), Research and development - Balancing val increase of 3% to $13.5M (expense), Stock-based Compensation in R&D increase of 14% to $779K (expense).